Horror autoinflammaticus: The molecular pathophysiology of autoinflammatory disease

Annual Review of Immunology

Volumn 27, Issue , 2009, Pages 621-668

  Masters, Seth L ^a   Simon, Anna ^b   Aksentijevich, Ivona ^a   Kastner, Daniel L ^a  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Ankylosing spondylitis; Atherosclerosis; Crohn's disease; IL 1 ; Inflammasome; Innate immunity; Pulmonary fibrosis; Type 2 diabetes mellitus

Indexed keywords

CANAKINUMAB; COLCHICINE; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; UNCLASSIFIED DRUG;

ANKYLOSING SPONDYLITIS; ATHEROSCLEROSIS; AUTOINFLAMMATORY DISEASE; AUTOSOMAL DOMINANT INHERITANCE; BACTERIAL ARTHRITIS; BLAU SYNDROME; CHEDIAK HIGASHI SYNDROME; CINCA SYNDROME; CLINICAL TRIAL; COMPLEMENT ACTIVATION; COMPLEMENT DISORDER; CROHN DISEASE; CRYOPYRINOPATHY; CRYSTAL STRUCTURE; CYTOTOXIC T LYMPHOCYTE; DRUG MECHANISM; ENTERITIS; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; FAMILIAL MEDITERRANEAN FEVER; FIBROUS DYSPLASIA; FOAM CELL; GENE IDENTIFICATION; GENE MUTATION; GOUT; GRISCELLI SYNDROME; GUADALOUPE PERIODIC FEVER; HEMOLYTIC UREMIC SYNDROME; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HUMAN; HYDATIDIFORM MOLE; HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME; INFLAMMASOMOPATHY; INNATE IMMUNITY; LYMPHOPROLIFERATIVE DISEASE; MACROPHAGE ACTIVATION; MUCKLE WELLS SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OCULAR ALBINISM; OSTEOMYELITIS; PAPA SYNDROME; PATHOPHYSIOLOGY; PFAPA SYNDROME; PRIORITY JOURNAL; PROTEIN FOLDING; PSEUDOGOUT; PYODERMA GANGRENOSUM; RECEPTOR BLOCKING; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SAPHO SYNDROME; SCHNITZLER SYNDROME; SIGNAL TRANSDUCTION; SPONDYLOARTHROPATHY;

ANIMALS; AUTOIMMUNE DISEASES; CARRIER PROTEINS; CYTOKINES; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; NF-KAPPA B; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); TUMOR NECROSIS FACTOR-ALPHA;

EID: 67650736238     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.25.022106.141627     Document Type: Review

References (252)

1. Ehrlich P. 1910. Studies in Immunity. London: Wiley
2. McDermott MF, Aksentijevich I, Galon J, McDermott EM, Ogunkolade BW, et al. 1999. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 97:133-44
3. International FMF Consortium. 1997. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Int. FMF Consort. Cell 90:797-807
4. French FMF Consortium. 1997. A candidate gene for familial Mediterranean fever. The French FMF Consort. Nat. Genet. 17:25-31
5. Houten SM, Kuis W, Duran M, de Koning TJ, van Royen-Kerkhof A, et al. 1999. Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome. Nat. Genet. 22:175-77
6. Drenth JP, Cuisset L, Grateau G, Vasseur C, van de Velde-Visser SD, et al. 1999. Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group. Nat. Genet. 22:178-81
7. Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. 2001. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat. Genet. 29:301-5
8. Galon J, Aksentijevich I, McDermott MF, O'Shea JJ, Kastner DL. 2000. TNFRSF1A mutations and autoinflammatory syndromes. Curr. Opin. Immunol. 12:479-86
9. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. 2005. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med. 201:1479-86
10. Thomas KT, Feder HM Jr, Lawton AR, Edwards KM. 1999. Periodic fever syndrome in children. J. Pediatr. 135:15-21
11. Shoham NG, Centola M, Mansfield E, Hull KM, Wood G, et al. 2003. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc. Natl. Acad. Sci. USA 100:13501-6
12. Ferguson PJ, El-Shanti HI. 2007. Autoinflammatory bone disorders. Curr. Opin. Rheumatol. 19:492-98
13. Medzhitov R, Janeway CA Jr. 1997. Innate immunity: the virtues of a nonclonal system of recognition. Cell 91:295-98
14. Feldmann J, Prieur AM, Quartier P, Berquin P, Certain S, et al. 2002. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am. J. Hum. Genet. 71:198-203
15. Aksentijevich I, Nowak M, Mallah M, Chae JJ, Watford WT, et al. 2002. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum. 46:3340-48
16. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. 2004. NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 20:319-25
17. Chae JJ, Komarow HD, Cheng J, Wood G, Raben N, et al. 2003. Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis. Mol. Cell 11:591-604
18. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. 2006. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440:237-41
19. Dostert C, Petrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J. 2008. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320:674-77
20. Cassel SL, Eisenbarth SC, Iyer SS, Sadler JJ, Colegio OR, et al. 2008. The Nalp3 inflammasome is essential for the development of silicosis. Proc. Natl. Acad. Sci. USA 105:9035-40
21. Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, et al. 2008. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat. Immunol. 9:847-56
22. Tschopp J, Martinon F, Burns K. 2003. NALPs: a novel protein family involved in inflammation. Nat. Rev. Mol. Cell Biol. 4:95-104
23. Martinon F, Tschopp J. 2005. NLRs join TLRs as innate sensors of pathogens. Trends Immunol. 26:447-54
24. Ting JP, Lovering RC, Alnemri ES, Bertin J, Boss JM, et al. 2008. The NLR gene family: a standard nomenclature. Immunity 28:285-87
25. McGonagle D, McDermott MF. 2006. A proposed classification of the immunological diseases. PLoS Med. 3:e297
26. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, et al. 2001. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411:599-603
27. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, et al. 2001. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411:603-6
28. Miceli-Richard C, Lesage S, Rybojad M, Prieur AM, Manouvrier-Hanu S, et al. 2001. CARD15 mutations in Blau syndrome. Nat. Genet. 29:19-20
29. Jeru I, Duquesnoy P, Fernandes-Alnemri T, Cochet E, Yu JW, et al. 2008. Mutations in NALP12 cause hereditary periodic fever syndromes. Proc. Natl. Acad. Sci. USA 105:1614-19
30. Lobito AA, Kimberley FC, Muppidi JR, Komarow H, Jackson AJ, et al. 2006. Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS). Blood 108:1320-27
31. Turner MJ, Delay ML, Bai S, Klenk E, Colbert RA. 2007.HLA-B27up- regulation causes accumulation of misfolded heavy chains and correlates with the magnitude of the unfolded protein response in transgenic rats: Implications for the pathogenesis of spondylarthritis-like disease. Arthritis Rheum. 56:215-23
32. Smith JA, Turner MJ, DeLay ML, Klenk EI, Sowders DP, Colbert RA. 2008. Endoplasmic reticulum stress and the unfolded protein response are linked to synergistic IFN-β induction via X-box binding protein 1. Eur J. Immunol. 38:1194-203
33. Layh-Schmitt G, Colbert RA. 2008. The interleukin-23/interleukin-17 axis in spondyloarthritis. Curr. Opin. Rheumatol. 20:392-97
34. Ueki Y, Tiziani V, Santanna C, Fukai N, Maulik C, et al. 2001. Mutations in the gene encoding c-Abl-binding protein SH3BP2 cause cherubism. Nat. Genet. 28:125-26
35. Ueki Y, Lin CY, Senoo M, Ebihara T, Agata N, et al. 2007. Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 "cherubism" mice. Cell 128:71-83
36. Zur Stadt U, Beutel K, Kolberg S, Schneppenheim R, Kabisch H, et al. 2006. Mutation spectrum in children with primary hemophagocytic lymphohistiocytosis: molecular and functional analyses of PRF1, UNC13D, STX11, and RAB27A. Hum. Mutat. 27:62-68
37. Janka GE. 2007. Familial and acquired hemophagocytic lymphohistiocytosis. Eur. J. Pediatr. 166:95-109
38. Hansson GK. 2005. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352:1685-95
39. Bertin J, DiStefano PS. 2000. The PYRIN domain: a novel motif found in apoptosis and inflammation proteins. Cell Death Differ. 7:1273-74
40. Martinon F, Hofmann K, Tschopp J. 2001. The pyrin domain: a possible member of the death domainfold family implicated in apoptosis and inflammation. Curr. Biol. 11:R118-20
41. Fairbrother WJ, Gordon NC, Humke EW, O'Rourke KM, Starovasnik MA, et al. 2001. The PYRIN domain: a member of the death domain-fold superfamily. Protein Sci. 10:1911-18
42. Martinon F, Burns K, Tschopp J. 2002. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-β. Mol. Cell 10:417-26
43. Keller M, Rüegg A, Werner S, Beer H-D. 2008. Active caspase-1 is a regulator of unconventional protein secretion. Cell 132:818-31
44. Faustin B, Lartigue L, Bruey JM, Luciano F, Sergienko E, et al. 2007. Reconstituted NALP1 inflammasome reveals two-step mechanism of caspase-1 activation. Mol. Cell 25:713-24
45. Duncan JA, Bergstralh DT, Wang Y, Willingham SB, Ye Z, Zimmermann AG, Ting JP. 2007. Cryopyrin/NALP3 binds ATP/dATP, is an ATPase, and requires ATP binding to mediate inflammatory signaling. Proc. Natl. Acad. Sci. USA 104:8041-46
46. Aksentijevich I, C DP, Remmers EF, Mueller JL, Le J, et al. 2007. The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum. 56:1273-85
47. Gattorno M, Tassi S, Carta S, Delfino L, Ferlito F, et al. 2007. Pattern of interleukin-1β secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. Arthritis Rheum. 56:3138-48
48. Ferrari D, Pizzirani C, Adinolfi E, Lemoli RM, Curti A, et al. 2006. The P2X7 receptor: a key player in IL-1 processing and release. J. Immunol. 176:3877-83
49. Pelegrin P, Barroso-Gutierrez C, Surprenant A. 2008. P2X7 receptor differentially couples to distinct release pathways for IL-1β in mouse macrophage. J. Immunol. 180:7147-57
50. Martinon F, Mayor A, Tschopp J. 2009. The inflammasomes: guardians of the body. Annu. Rev. Immunol. 27:229-65
51. Mariathasan S, Weiss DS, Newton K, McBride J, O'Rourke K, et al. 2006. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440:228-32
52. Sutterwala FS, Ogura Y, Szczepanik M, Lara-Tejero M, Lichtenberger GS, et al. 2006. Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 24:317-27
53. Kanneganti TD, Ozoren N, Body-Malapel M, Amer A, Park JH, et al. 2006. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 440:233-36
54. Kanneganti TD, Body-Malapel M, Amer A, Park JH, Whitfield J, et al. 2006. Critical role for Cryopyrin/Nalp3 in activation of caspase-1 in response to viral infection and double-stranded RNA. J. Biol. Chem. 281:36560-68
55. Edele F, Esser PR, Lass C, Laszczyk MN, Oswald E, et al. 2007. Innate and adaptive immune responses in allergic contact dermatitis and autoimmune skin diseases. Inflamm. Allergy Drug Targets 6:236-44
56. Willingham SB, Bergstralh DT, O'Connor W, Morrison AC, Taxman DJ, et al. 2007. Microbial pathogen-induced necrotic cell death mediated by the inflammasome components CIAS1/cryopyrin/NLRP3 and ASC. Cell Host Microbe 2:147-59
57. Fujisawa A, Kambe N, Saito M, Nishikomori R, Tanizaki H, et al. 2007. Disease-associated mutations in CIAS1 induce cathepsin B-dependent rapid cell death of human THP-1 monocytic cells. Blood 109:2903-11
58. Saito M, Nishikomori R, Kambe N, Fujisawa A, Tanizaki H, et al. 2008. Disease-associated CIAS1 mutations induce monocyte death, revealing low-level mosaicism in mutation-negative cryopyrin-associated periodic syndrome patients. Blood 111:2132-41
59. Saito M, Fujisawa A, Nishikomori R, Kambe N, Nakata-Hizume M, et al. 2005. Somatic mosaicism of CIAS1 in a patient with chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum. 52:3579-85
60. Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, et al. 2006. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1β inhibition. N. Engl. J. Med. 355:581-92
61. Goldbach-Mansky R, Shroff SD, Wilson M, Snyder C, Plehn S, et al. 2008. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum. 58:2432-42
62. Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ, et al. 2008. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum. 58:2443-52
63. Alten R, Gram H, Joosten LA, Van Den Berg WB, Sieper J, et al. 2008. The human anti-IL-1β monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res. Ther. 10:R67
64. Pras E, Aksentijevich I, Gruberg L, Balow JE Jr, Prosen L, et al. 1992. Mapping of a gene causing familial Mediterranean fever to the short arm of chromosome 16. N. Engl. J. Med. 326:1509-13
65. Kastner DL. 1998. Familial Mediterranean fever: the genetics of inflammation. Hosp. Pract. 33:131-34, 9-40, 43-46 passim
66. Lachmann HJ, Sengul B, Yavuzsen TU, Booth DR, Booth SE, et al. 2006. Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology 45:746-50
67. Kalyoncu M, Acar BC, Cakar N, Bakkaloglu A, Ozturk S, et al. 2006. Are carriers for MEFV mutations "healthy"? Clin. Exp. Rheumatol. 24:S120-22
68. Booth DR, Gillmore JD, Lachmann HJ, Booth SE, Bybee A, et al. 2000. The genetic basis of autosomal dominant familial Mediterranean fever. QJM 93:217-21
69. Touitou I, Lesage S, McDermott M, Cuisset L, Hoffman H, et al. 2004. Infevers: an evolving mutation database for auto-inflammatory syndromes. Hum. Mutat. 24:194-98
70. Milhavet F, Cuisset L, Hoffman HM, Slim R, El-Shanti H, et al. 2008. The infevers autoinflammatory mutation online registry: update with new genes and functions. Hum. Mutat. 29:803-8
71. Nisole S, Stoye JP, Saib A. 2005. TRIM family proteins: retroviral restriction and antiviral defence. Nat. Rev. Microbiol. 3:799-808
72. Centola M, Aksentijevich I, Kastner DL. 1998. The hereditary periodic fever syndromes: molecular analysis of a new family of inflammatory diseases. Hum. Mol. Genet. 7:1581-88
73. Diaz A, Hu C, Kastner DL, Schaner P, Reginato AM, et al. 2004. Lipopolysaccharide-induced expression of multiple alternatively spliced MEFV transcripts in human synovial fibroblasts: a prominent splice isoform lacks the C-terminal domain that is highly mutated in familial Mediterranean fever. Arthritis Rheum. 50:3679-89
74. Chae JJ, Wood G, Richard K, Jaffe H, Colburn NT, et al. 2008. The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF-κB through its N-terminal fragment. Blood 112:1794-803
75. Mansfield E, Chae JJ, Komarow HD, Brotz TM, Frucht DM, et al. 2001. The familial Mediterranean fever protein, pyrin, associates with microtubules and colocalizes with actin filaments. Blood 98:851-59
76. Goldfinger SE. 1972. Colchicine for familial Mediterranean fever. N. Engl. J. Med. 287:1302
77. Richards N, Schaner P, Diaz A, Stuckey J, Shelden E, et al. 2001. Interaction between pyrin and the apoptotic speck protein (ASC) modulates ASC-induced apoptosis. J. Biol. Chem. 276:39320-29
78. Martinon F, Tschopp J. 2004. Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell 117:561-74
79. Yu JW, Wu J, Zhang Z, Datta P, Ibrahimi I, et al. 2006. Cryopyrin and pyrin activate caspase-1, but not NF-κB, via ASC oligomerization. Cell Death Differ. 13:236-49
80. Chae JJ, Wood G, Masters SL, Richard K, Park G, et al. 2006. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1β production. Proc. Natl. Acad. Sci. USA 103:9982-87
81. Papin S, Cuenin S, Agostini L, Martinon F, Werner S, et al. 2007. The SPRY domain of Pyrin, mutated in familial Mediterranean fever patients, interacts with inflammasome components and inhibits proIL-1β processing. Cell Death Differ. 14:1457-66
82. Seshadri S, Duncan MD, Hart JM, Gavrilin MA, Wewers MD. 2007. Pyrin levels in human monocytes and monocyte-derived macrophages regulate IL-1β processing and release. J. Immunol. 179:1274-81
83. Hall MW, Gavrilin MA, Knatz NL, Duncan MD, Fernandez SA, Wewers MD. 2007. Monocyte mRNA phenotype and adverse outcomes from pediatric multiple organ dysfunction syndrome. Pediatr. Res. 62:597-603
84. Ustek D, Ekmekci CG, Selcukbiricik F, Cakiris A, Oku B, et al. 2007. Association between reduced levels of MEFV messenger RNA in peripheral blood leukocytes and acute inflammation. Arthritis Rheum. 56:345-50
85. Belkhir R, Moulonguet-Doleris L, Hachulla E, Prinseau J, Baglin A, Hanslik T. 2007. Treatment of familial Mediterranean fever with anakinra. Ann. Intern. Med. 146:825-26
86. Calligaris L, Marchetti F, Tommasini A, Ventura A. 2008. The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. Eur. J. Pediatr. 167:695-96
87. Gattringer R, Lagler H, Gattringer KB, Knapp S, Burgmann H, et al. 2007. Anakinra in two adolescent female patients suffering from colchicine-resistant familial Mediterranean fever: effective but risky. Eur. J. Clin. Invest. 37:912-14
88. Kuijk LM, Govers AM, Frenkel J, Hofhuis WJ. 2007. Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra. Ann. Rheum. Dis. 66:1545-46
89. Roldan R, Ruiz AM, Miranda MD, Collantes E. 2008. Anakinra: new therapeutic approach in children with familial Mediterranean fever resistant to colchicine. Joint Bone Spine 75:504-5
90. Chae JJ, Centola M, Aksentijevich I, Dutra A, Tran M, et al. 2000. Isolation, genomic organization, and expression analysis of the mouse and rat homologs of MEFV, the gene for familial Mediterranean fever. Mamm. Genome 11:428-35
91. Uchil PD, Quinlan BD, Chan WT, Luna JM, Mothes W. 2008. TRIM E3 ligases interfere with early and late stages of the retroviral life cycle. PLoS Pathog. 4:e16
92. Schaner P, Richards N, Wadhwa A, Aksentijevich I, Kastner D, et al. 2001. Episodic evolution of pyrin in primates: human mutations recapitulate ancestral amino acid states. Nat. Genet. 27:318-21
93. Masters SL, Yao S, Willson TA, Zhang JG, Palmer KR, et al. 2006. The SPRY domain of SSB-2 adopts a novel fold that presents conserved Par-4-binding residues. Nat. Struct. Mol. Biol. 13:77-84
94. Keeble AH, Khan Z, Forster A, James LC. 2008. TRIM21 is an IgG receptor that is structurally, thermodynamically, and kinetically conserved. Proc. Natl. Acad. Sci. USA 105:6045-50
95. Woo JS, Suh HY, Park SY, Oh BH. 2006. Structural basis for protein recognition by B30.2/SPRY domains. Mol. Cell 24:967-76
96. Lindor NM, Arsenault TM, Solomon H, Seidman CE, McEvoy MT. 1997. A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome. Mayo Clin. Proc. 72:611-15
97. Wise CA, Bennett LB, Pascual V, Gillum JD, Bowcock AM. 2000. Localization of a gene for familial recurrent arthritis. Arthritis Rheum. 43:2041-45
98. Wise CA, Gillum JD, Seidman CE, Lindor NM, Veile R, et al. 2002. Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum. Mol. Genet. 11:961-69
99. Yu JW, Fernandes-Alnemri T, Datta P, Wu J, Juliana C, et al. 2007. Pyrin activates the ASC pyroptosome in response to engagement by autoinflammatory PSTPIP1 mutants. Mol. Cell 28:214-27
100. Fernandes-Alnemri T, Wu J, Yu JW, Datta P, Miller B, et al. 2007. The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. Cell Death Differ. 14:1590-604
101. Dierselhuis MP, Frenkel J, Wulffraat NM, Boelens JJ. 2005. Anakinra for flares of pyogenic arthritis in PAPA syndrome. Rheumatology 44:406-8
102. Badour K, Zhang J, Shi F, Leng Y, Collins M, Siminovitch KA. 2004. Fyn and PTP-PEST-mediated regulation of Wiskott-Aldrich syndrome protein (WASp) tyrosine phosphorylation is required for coupling T cell antigen receptor engagement to WASp effector function and T cell activation. J. Exp. Med. 199:99-112
103. Yang H, Reinherz EL. 2006. CD2BP1 modulates CD2-dependent T cell activation via linkage to protein tyrosine phosphatase (PTP)-PEST. J. Immunol. 176:5898-907
104. Baum W, Kirkin V, Fernandez SB, Pick R, Lettau M, et al. 2005. Binding of the intracellular Fas ligand (FasL) domain to the adaptor protein PSTPIP results in a cytoplasmic localization of FasL. J. Biol. Chem. 280:40012-24
105. Byrd L, Grossmann M, Potter M, Shen-Ong GL. 1991. Chronic multifocal osteomyelitis, a new recessive mutation on chromosome 18 of the mouse. Genomics 11:794-98
106. Ferguson PJ, Bing X, Vasef MA, Ochoa LA, Mahgoub A, et al. 2006. A missense mutation in pstpip2 is associated with the murine autoinflammatory disorder chronic multifocal osteomyelitis. Bone 38:41-47
107. El-Shanti HI, Ferguson PJ. 2007. Chronic recurrent multifocal osteomyelitis: a concise review and genetic update. Clin. Orthop. Relat. Res. 462:11-19
108. Jansson A, Renner ED, Ramser J, Mayer A, Haban M, et al. 2007. Classification of nonbacterial osteitis: retrospective study of clinical, immunological and genetic aspects in 89 patients. Rheumatology 46:154-60
109. Grosse J, Chitu V, Marquardt A, Hanke P, Schmittwolf C, et al. 2006. Mutation of mouse Mayp/Pstpip2 causes a macrophage autoinflammatory disease. Blood 107:3350-58
110. Golla A, Jansson A, Ramser J, Hellebrand H, Zahn R, et al. 2002. Chronic recurrent multifocal osteomyelitis (CRMO): evidence for a susceptibility gene located on chromosome 18q21.3-18q22. Eur. J. Hum. Genet. 10:217-21
111. Hoffmann G, Gibson KM, Brandt IK, Bader PI, Wappner RS, Sweetman L. 1986. Mevalonic aciduria - an inborn error of cholesterol and nonsterol isoprene biosynthesis. N. Engl. J. Med. 314:1610-14
112. Bodar EJ, Van Der Hilst JC, van Heerde W, Van Der Meer JW, Drenth JP, Simon A. 2007. Defective apoptosis of peripheral-blood lymphocytes in hyper-IgD and periodic fever syndrome. Blood 109:2416-18
113. Kuijk LM, Beekman JM, Koster J, Waterham HR, Frenkel J, Coffer PJ. 2008. HMG-CoA reductase inhibition induces IL-1β release through Rac1/PI3K/PKB-dependent caspase-1 activation. Blood 112:3563-73
114. Hager EJ, Tse HM, Piganelli JD, Gupta M, Baetscher M, et al. 2007. Deletion of a single mevalonate kinase (Mvk) allele yields a murine model of hyper-IgD syndrome. J. Inherit. Metab. Dis. 30:888-95
115. Simon A, Bijzet J, Voorbij HA, Mantovani A, Van Der Meer JW, Drenth JP. 2004. Effect of inflammatory attacks in the classical type hyper-IgD syndrome on immunoglobulin D, cholesterol and parameters of the acute phase response. J. Intern. Med. 256:247-53
116. Simon A, van Deuren M, Tighe PJ, Van Der Meer JW, Drenth JP. 2001. Genetic analysis as a valuable key to diagnosis and treatment of periodic fever. Arch. Intern. Med. 161:2491-93
117. Bodar EJ, Van Der Hilst JC, Drenth JP, Van Der Meer JW, Simon A. 2005. Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. Neth. J. Med. 63:260-64
118. Cailliez M, Garaix F, Rousset-Rouviere C, Bruno D, Kone-Paut I, et al. 2006. Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis. J. Inherit. Metab. Dis. 29:763
119. Mandey SH, Schneiders MS, Koster J, Waterham HR. 2006. Mutational spectrum and genotypephenotype correlations in mevalonate kinase deficiency. Hum. Mutat. 27:796-802
120. Slim R, Mehio A. 2007. The genetics of hydatidiform moles: new lights on an ancient disease. Clin. Genet. 71:25-34
121. El-Maarri O, Slim R. 2006. Familial hydatidiform molar pregnancy: the germline imprinting defect hypothesis? Curr. Top. Microbiol. Immunol. 301:229-41
122. Murdoch S, Djuric U, Mazhar B, Seoud M, Khan R, et al. 2006. Mutations in NALP7 cause recurrent hydatidiform moles and reproductive wastage in humans. Nat. Genet. 38:300-2
123. Kinoshita T, Wang Y, Hasegawa M, Imamura R, Suda T. 2005. PYPAF3, a PYRIN-containing APAF-1-like protein, is a feedback regulator of caspase-1-dependent interleukin-1β secretion. J. Biol. Chem. 280:21720-25
124. Mor G. 2008. Inflammation and pregnancy: the role of Toll-like receptors in trophoblast-immune interaction. Ann. NY Acad. Sci. 1127:121-28
125. Caucheteux SM, Kanellopoulos-Langevin C, Ojcius DM. 2003. At the innate frontiers between mother and fetus: linking abortion with complement activation. Immunity 18:169-72
126. Murtha AP, Nieves A, Hauser ER, Swamy GK, Yonish BA, et al. 2006. Association of maternal IL-1 receptor antagonist intron 2 gene polymorphism and preterm birth. Am. J. Obstet. Gynecol. 195:1249-53
127. Santtila S, Savinainen K, Hurme M. 1998. Presence of the IL-1RA allele 2 (IL1RN*2) is associated with enhanced IL-1β production in vitro. Scand. J. Immunol. 47:195-98
128. Kou YC, Shao L, Peng HH, Rosetta R, del Gaudio D, et al. 2008. A recurrent intragenic genomic duplication, other novel mutations inNLRP7and imprinting defects in recurrent biparental hydatidiform moles. Mol. Hum. Reprod. 14:33-40
129. Qian J, Deveault C, Bagga R, Xie X, Slim R. 2007.Women heterozygous for NALP7/NLRP7 mutations are at risk for reproductive wastage: report of two novel mutations. Hum. Mutat. 28:741
130. Chen CJ, Shi Y, Hearn A, Fitzgerald K, Golenbock D, et al. 2006. MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J. Clin. Invest. 116:2262-71
131. McGonagle D, Tan AL, Shankaranarayana S, Madden J, Emery P, McDermott MF. 2007. Management of treatment resistant inflammation of acute or chronic tophaceous gout with anakinra. Ann. Rheum. Dis. 66:1683-84
132. So A, De Smedt T, Revaz S, Tschopp J. 2007. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res. Ther. 9:R28
133. Cowper SE, Kuo PH, Bucala R. 2007. Nephrogenic systemic fibrosis and gadolinium exposure: association and lessons for idiopathic fibrosing disorders. Arthritis Rheum. 56:3173-75
134. Armanios MY, Chen JJ, Cogan JD, Alder JK, Ingersoll RG, et al. 2007. Telomerase mutations in families with idiopathic pulmonary fibrosis. N. Engl. J. Med. 356:1317-26
135. Afeltra A, Gentilucci UV, Rabitti C, Amoroso A, Caricato M, et al. 2005. Retroperitoneal fibrosis and ankylosing spondylitis: which links? Semin. Arthritis Rheum. 35:43-48
136. Perkins RC, Scheule RK, Hamilton R, Gomes G, Freidman G, Holian A. 1993. Human alveolar macrophage cytokine release in response to in vitro and in vivo asbestos exposure. Exp. Lung Res. 19:55-65
137. Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, et al. 2008. The NALP3 inflammasome is involved in the innate immune response to amyloid-β. Nat. Immunol. 9:857-65
138. Lawson WE, Loyd JE. 2006. The genetic approach in pulmonary fibrosis: Can it provide clues to this complex disease? Proc. Am. Thorac. Soc. 3:345-49
139. Whyte M, Hubbard R, Meliconi R, Whidborne M, Eaton V, et al. 2000. Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-α gene polymorphisms. Am. J. Respir. Crit. Care Med. 162:755-58
140. Gasse P, Mary C, Guenon I, Noulin N, Charron S, et al. 2007. IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice. J. Clin. Invest. 117:3786-99
141. Eisenbarth GS. 2007. Update in type 1 diabetes. J. Clin. Endocrinol. Metab. 92:2403-7
142. Stumvoll M, Goldstein BJ, van Haeften TW. 2005. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365:1333-46
143. Pickup JC, Mattock MB, Chusney GD, Burt D. 1997. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40:1286-92
144. Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann MM, et al. 2003. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 52:812-17
145. Maedler K, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka HI, et al. 2002. Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets. J. Clin. Invest. 110:851-60
146. Sauter NS, Schulthess FT, Galasso R, Castellani LW, Maedler K. 2008. The antiinflammatory cytokine interleukin-1 receptor antagonist protects from high-fat diet-induced hyperglycemia. Endocrinology 149:2208-18
147. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, et al. 2007. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 356:1517-26
148. de Koning HD, Bodar EJ, Van Der Meer JW, Simon A. 2007. Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin. Arthritis Rheum. 37:137-48
149. Ryan JG, de Koning HD, Beck LA, Booty MG, Kastner DL, Simon A. 2008. IL-1 blockade in Schnitzler syndrome: ex vivo findings correlate with clinical remission. J. Allergy Clin. Immunol. 121:260-62
150. Dybowski F, Sepp N, Bergerhausen HJ, Braun J. 2008. Successful use of anakinra to treat refractory Schnitzler's syndrome. Clin. Exp. Rheumatol. 26:354-57
151. Frischmeyer-Guerrerio PA, Rachamalla R, Saini SS. 2008. Remission of Schnitzler syndrome after treatment with anakinra. Ann. Allergy Asthma Immunol. 100:617-19
152. Gilson M, Abad S, Larroche C, Dhote R. 2007. Treatment of Schnitzler's syndrome with anakinra. Clin. Exp. Rheumatol. 25:931
153. Wastiaux H, Barbarot S, Gagey-Caron V, Berthelot JM, Hamidou M, Stalder JF. 2008. Schnitzler syndrome: a dramatic improvement with anakinra. J. Eur. Acad. Dermatol. Venereol. In press
154. Jin Y, Mailloux CM, Gowan K, Riccardi SL, LaBerge G, et al. 2007. NALP1 in vitiligo-associated multiple autoimmune disease. N. Engl. J. Med. 356:1216-25
155. Granell M, Urbano-Ispizua A, Pons A, Arostegui JI, Gel B, et al. 2008. Common variants in NLRP2 and NLRP3 genes are strong prognostic factors for the outcome of HLA-identical sibling allogeneic stem cell transplantation. Blood 112:4337-42
156. Holler E, Rogler G, Herfarth H, Brenmoehl J, Wild PJ, et al. 2004. Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation. Blood 104:889-94
157. Inohara N, Ogura Y, Chen FF, Muto A, Nunez G. 2001. Human Nod1 confers responsiveness to bacterial lipopolysaccharides. J. Biol. Chem. 276:2551-54
158. Inohara N, Ogura Y, Fontalba A, Gutierrez O, Pons F, et al. 2003. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J. Biol. Chem. 278:5509-12
159. Barrat FJ, Meeker T, Gregorio J, Chan JH, Uematsu S, et al. 2005. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med. 202:1131-39
160. Pisitkun P, Deane JA, Difilippantonio MJ, Tarasenko T, Satterthwaite AB, Bolland S. 2006. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 312:1669-72
161. Subramanian S, Tus K, Li QZ, Wang A, Tian XH, et al. 2006. A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. Proc. Natl. Acad. Sci. USA 103:9970-75
162. Krieg AM. 2007. The Toll of too much TLR7. Immunity 27:695-97
163. Cho JH. 2008. The genetics and immunopathogenesis of inflammatory bowel disease. Nat. Rev. Immunol. 8:458-66
164. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, et al. 2008. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat. Genet. 40:955-62
165. Fisher SA, Tremelling M, Anderson CA, Gwilliam R, Bumpstead S, et al. 2008. Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. Nat. Genet. 40:710-12
166. Franke A, Balschun T, Karlsen TH, Hedderich J, May S, et al. 2008. Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis. Nat. Genet. 40:713-15
167. Franke A, Balschun T, Karlsen TH, Sventoraityte J, Nikolaus S, et al. 2008. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat. Genet. 40:1319-23
168. Inohara N, Chamaillard M, McDonald C, Nuñez G. 2005. NOD-LRR proteins: role in host-microbial interactions and inflammatory disease. Annu. Rev. Biochem. 74:355-83
169. Lesage S, Zouali H, Cezard JP, Colombel JF, Belaiche J, et al. 2002. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am. J. Hum. Genet. 70:845-57
170. Schreiber S, Nikolaus S, Hampe J. 1998. Activation of nuclear factor kB inflammatory bowel disease. Gut 42:477-84
171. Li J, Moran T, Swanson E, Julian C, Harris J, et al. 2004. Regulation of IL-8 and IL-1β expression in Crohn's disease associated NOD2/CARD15 mutations. Hum. Mol. Genet. 13:1715-25
172. van Heel DA, Ghosh S, Butler M, Hunt KA, Lundberg AM, et al. 2005. Muramyl dipeptide and Toll-like receptor sensitivity in NOD2-associated Crohn's disease. Lancet 365:1794-96
173. Maeda S, Hsu LC, Liu H, Bankston LA, Iimura M, et al. 2005. Nod2 mutation in Crohn's disease potentiates NF-κB activity and IL-1β processing. Science 307:734-38
174. Marks DJ, Harbord MW, MacAllister R, Rahman RZ, Young J, et al. 2006. Defective acute inflammation in Crohn's disease: a clinical investigation. Lancet 367:668-78
175. Kobayashi KS, Chamaillard M, Ogura Y, Henegariu O, Inohara N, et al. 2005. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 307:731-34
176. Simms LA, Doecke JD, Walsh MD, Huang N, Fowler EV, Radford-Smith GL. 2008. Reduced alphadefensin expression is associated with inflammation and not NOD2 mutation status in ileal Crohn's disease. Gut 57:903-10
177. Pauleau AL, Murray PJ. 2003. Role of nod2 in the response of macrophages to Toll-like receptor agonists. Mol. Cell Biol. 23:7531-39
178. Watanabe T, Asano N, Murray PJ, Ozato K, Tailor P, et al. 2008. Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis. J. Clin. Invest. 118:545-59
179. Cadwell K, Liu JY, Brown SL, Miyoshi H, Loh J, et al. 2008. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature 456:259-63
180. Saitoh T, Fujita N, Jang MH, Uematsu S, Yang BG, et al. 2008. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1β production. Nature 456:264-68
181. Kanazawa N, Okafuji I, Kambe N, Nishikomori R, Nakata-Hizume M, et al. 2005. Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-κB activation: common genetic etiology with Blau syndrome. Blood 105:1195-97
182. Wang X, Kuivaniemi H, Bonavita G, Mutkus L, Mau U, et al. 2002. CARD15 mutations in familial granulomatosis syndromes: a study of the original Blau syndrome kindred and other families with largevessel arteritis and cranial neuropathy. Arthritis Rheum. 46:3041-45
183. Arostegui JI, Arnal C, Merino R, Modesto C, Antonia Carballo M, et al. 2007. NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort. Arthritis Rheum. 56:3805-13
184. Albrecht M, Lengauer T, Schreiber S. 2003. Disease-associated variants in PYPAF1 and NOD2 result in similar alterations of conserved sequence. Bioinformatics 19:2171-75
185. Williams KL, Lich JD, Duncan JA, Reed W, Rallabhandi P, et al. 2005. The CATERPILLER protein monarch-1 is an antagonist of Toll-like receptor-, tumor necrosis factorα-, and Mycobacterium tuberculosis-induced proinflammatory signals. J. Biol. Chem. 280:39914-24
186. Hull KM, Drewe E, Aksentijevich I, Singh HK, Wong K, et al. 2002. The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine 81:349-68
187. Hull KM, Wong K, Wood GM, Chu WS, Kastner DL. 2002. Monocytic fasciitis: a newly recognized clinical feature of tumor necrosis factor receptor dysfunction. Arthritis Rheum. 46:2189-94
188. Aksentijevich I, Galon J, Soares M, Mansfield E, Hull K, et al. 2001. The tumor-necrosis-factor receptorassociated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. Am. J. Hum. Genet. 69:301-14
189. Mullberg J, Durie FH, Otten-Evans C, Alderson MR, Rose-John S, et al. 1995. A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. J. Immunol. 155:5198-205
190. Huggins ML, Radford PM, McIntosh RS, Bainbridge SE, Dickinson P, et al. 2004. Shedding of mutant tumor necrosis factor receptor superfamily 1A associated with tumor necrosis factor receptor-associated periodic syndrome: differences between cell types. Arthritis Rheum. 50:2651-59
191. Todd I, Radford PM, Draper-Morgan KA, McIntosh R, Bainbridge S, et al. 2004. Mutant forms of tumour necrosis factor receptor I that occur in TNF-receptor-associated periodic syndrome retain signalling functions but show abnormal behaviour. Immunology 113:65-79
192. Todd I, Radford PM, Daffa N, Bainbridge SE, Powell RJ, Tighe PJ. 2007. Mutant tumor necrosis factor receptor associated with tumor necrosis factor receptor-associated periodic syndrome is altered antigenically and is retained within patients' leukocytes. Arthritis Rheum. 56:2765-73
193. Rebelo SL, Bainbridge SE, Amel-Kashipaz MR, Radford PM, Powell RJ, et al. 2006. Modeling of tumor necrosis factor receptor superfamily 1A mutants associated with tumor necrosis factor receptor-associated periodic syndrome indicates misfolding consistent with abnormal function. Arthritis Rheum. 54:2674-87
194. Kriegel MA, Huffmeier U, Scherb E, Scheidig C, Geiler T, et al. 2003. Tumor necrosis factor receptorassociated periodic syndrome characterized by a mutation affecting the cleavage site of the receptor: implications for pathogenesis. Arthritis Rheum. 48:2386-88
195. Stojanov S, Dejaco C, Lohse P, Huss K, Duftner C, et al. 2008. Clinical and functional characterisation of a novel TNFRSF1A c.605T>A/V173D cleavage site mutation associated with tumour necrosis factor receptor-associated periodic fever syndrome (TRAPS), cardiovascular complications and excellent response to etanercept treatment. Ann. Rheum. Dis. 67:1292-98
196. Xu C, Bailly-Maitre B, Reed JC. 2005. Endoplasmic reticulum stress: cell life and death decisions. J. Clin. Invest. 115:2656-64
197. Simon A, Bodar EJ, Van Der Hilst JC, Van Der Meer JW, Fiselier TJ, et al. 2004. Beneficial response to interleukin 1 receptor antagonist in traps. Am. J. Med. 117:208-10
198. Gattorno M, Pelagatti MA, Meini A, Obici L, Barcellona R, et al. 2008. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum. 58:1516-20
199. Sacre K, Brihaye B, Lidove O, Papo T, Pocidalo MA, et al. 2008. Dramatic improvement following interleukin 1β blockade in tumor necrosis factor receptor-1-associated syndrome (TRAPS) resistant to anti-TNF-α therapy. J. Rheumatol. 35:357-58
200. Sims AM, Wordsworth BP, Brown MA. 2004. Genetic susceptibility to ankylosing spondylitis. Curr. Mol. Med. 4:13-20
201. Turner MJ, Colbert RA. 2002. HLA-B27 and pathogenesis of spondyloarthropathies. Curr. Opin. Rheumatol. 14:367-72
202. Dangoria NS, DeLay ML, Kingsbury DJ, Mear JP, Uchanska-Ziegler B, et al. 2002. HLA-B27 misfolding is associated with aberrant intermolecular disulfide bond formation (dimerization) in the endoplasmic reticulum. J. Biol. Chem. 277:23459-68
203. Colbert RA. 2004. The immunobiology of HLA-B27: variations on a theme. Curr. Mol. Med. 4:21-30
204. Tran TM, Satumtira N, Dorris ML, May E, Wang A, et al. 2004. HLA-B27 in transgenic rats forms disulfide-linked heavy chain oligomers and multimers that bind to the chaperone BiP. J. Immunol. 172:5110-19
205. Turner MJ, Sowders DP, DeLay ML, Mohapatra R, Bai S, et al. 2005. HLA-B27 misfolding in transgenic rats is associated with activation of the unfolded protein response. J. Immunol. 175:2438-48
206. Taurog JD. 2007. The mystery of HLA-B27: If it isn't one thing, it's another. Arthritis Rheum. 56:2478-81
207. Galocha B, de Castro JA. 2008. Folding of HLA-B27 subtypes is determined by the global effect of polymorphic residues and shows incomplete correspondence to ankylosing spondylitis. Arthritis Rheum. 58:401-12
208. Sims AM, Timms AE, Bruges-Armas J, Burgos-Vargas R, Chou CT, et al. 2008. Prospective meta-analysis of interleukin 1 gene complex polymorphisms confirms associations with ankylosing spondylitis. Ann. Rheum. Dis. 67:1305-9
209. Burton PR, Clayton DG, Cardon LR, Craddock N, Deloukas P, et al. 2007. Association scan of 14500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat. Genet. 39:1329-37
210. Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, et al. 2007. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am. J. Hum. Genet. 80:273-90
211. Chen Z, O'Shea JJ. 2008. Th17 cells: a new fate for differentiating helperTcells. Immunol. Res. 41:87-102
212. Loirat C, Noris M, Fremeaux-Bacchi V. 2008. Complement and the atypical hemolytic uremic syndrome in children. Pediatr. Nephrol. 23:1957-72
213. Tarr PI, Gordon CA, Chandler WL. 2005. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 365:1073-86
214. Ohali M, Shalev H, Schlesinger M, Katz Y, Kachko L, et al. 1998. Hypocomplementemic autosomal recessive hemolytic uremic syndrome with decreased factor H. Pediatr. Nephrol. 12:619-24
215. Warwicker P, Goodship TH, Donne RL, Pirson Y, Nicholls A, et al. 1998. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int. 53:836-44
216. Noris M, Brioschi S, Caprioli J, Todeschini M, Bresin E, et al. 2003. Familial haemolytic uraemic syndrome and an MCP mutation. Lancet 362:1542-47
217. Richards A, Kemp EJ, Liszewski MK, Goodship JA, Lampe AK, et al. 2003. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc. Natl. Acad. Sci. USA 100:12966-71
218. Kavanagh D, Kemp EJ, Mayland E, Winney RJ, Duffield JS, et al. 2005. Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 16:2150-55
219. Gros P, Milder FJ, Janssen BJ. 2008. Complement driven by conformational changes. Nat. Rev. Immunol. 8:48-58
220. Jokiranta TS, Jaakola VP, Lehtinen MJ, Parepalo M, Meri S, Goldman A. 2006. Structure of complement factor H carboxyl-terminus reveals molecular basis of atypical haemolytic uremic syndrome. EMBO J. 25:1784-94
221. Edwards AO, Ritter R III, Abel KJ, Manning A, Panhuysen C, Farrer LA. 2005. Complement factor H polymorphism and age-related macular degeneration. Science 308:421-24
222. Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, et al. 2005. Complement factor H variant increases the risk of age-related macular degeneration. Science 308:419-21
223. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, et al. 2005. Complement factor H polymorphism in age-related macular degeneration. Science 308:385-89
224. Hollyfield JG, Bonilha VL, Rayborn ME, Yang X, Shadrach KG, et al. 2008. Oxidative damage-induced inflammation initiates age-related macular degeneration. Nat. Med. 14:194-98
225. Novack DV, Faccio R. 2007. Jawing about TNF: new hope for cherubism. Cell 128:15-17
226. Filipovich AH. 2008. Hemophagocytic lymphohistiocytosis and other hemophagocytic disorders. Immunol. Allergy Clin. North Am. 28:293-313, viii
227. Kelly A, Ramanan AV. 2007. Recognition and management of macrophage activation syndrome in juvenile arthritis. Curr. Opin. Rheumatol. 19:477-81
228. Fall N, Barnes M, Thornton S, Luyrink L, Olson J, et al. 2007. Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis Rheum. 56:3793-804
229. Schaer DJ, Schleiffenbaum B, Kurrer M, Imhof A, Bachli E, et al. 2005. Soluble hemoglobin-haptoglobin scavenger receptor CD163 as a lineage-specific marker in the reactive hemophagocytic syndrome. Eur. J. Haematol. 74:6-10
230. Stepp SE, Dufourcq-Lagelouse R, Le Deist F, Bhawan S, Certain S, et al. 1999. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 286:1957-59
231. Feldmann J, Callebaut I, Raposo G, Certain S, Bacq D, et al. 2003. Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell 115:461-73
232. Bryceson YT, Rudd E, Zheng C, Edner J, Ma D, et al. 2007. Defective cytotoxic lymphocyte degranulation in syntaxin-11 deficient familial hemophagocytic lymphohistiocytosis 4 (FHL4) patients. Blood 110:1906-15
233. Westbroek W, Adams D, Huizing M, Koshoffer A, Dorward H, et al. 2007. Cellular defects in Chediak-Higashi syndrome correlate with the molecular genotype and clinical phenotype. J. Invest. Dermatol. 127:2674-77
234. Enders A, Zieger B, Schwarz K, Yoshimi A, Speckmann C, et al. 2006. Lethal hemophagocytic lymphohistiocytosis in Hermansky-Pudlak syndrome type II. Blood 108:81-87
235. Grom AA. 2004. Natural killer cell dysfunction: A common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis? Arthritis Rheum. 50:689-98
236. Donn R, Ellison S, Lamb R, Day T, Baildam E, Ramanan AV. 2008. Genetic loci contributing to hemophagocytic lymphohistiocytosis do not confer susceptibility to systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 58:869-74
237. Zhang K, Biroschak J, Glass DN, Thompson SD, Finkel T, et al. 2008. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms. Arthritis Rheum. 58:2892-96
238. Ross R. 1999. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340:115-26
239. Yan ZQ, Hansson GK. 2007. Innate immunity, macrophage activation, and atherosclerosis. Immunol. Rev. 219:187-203
240. Zhou X, Robertson AK, Hjerpe C, Hansson GK. 2006. Adoptive transfer of CD4+ T cells reactive to modified low-density lipoprotein aggravates atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 26:864-70
241. Wang X, Ria M, Kelmenson PM, Eriksson P, Higgins DC, et al. 2005. Positional identification of TNFSF4, encoding OX40 ligand, as a gene that influences atherosclerosis susceptibility. Nat. Genet. 37:365-72
242. Febbraio M, Podrez EA, Smith JD, Hajjar DP, Hazen SL, et al. 2000. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J. Clin. Invest. 105:1049-56
243. Moore KJ, Kunjathoor VV, Koehn SL, Manning JJ, Tseng AA, et al. 2005. Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice. J. Clin. Invest. 115:2192-201
244. Devlin CM, Kuriakose G, Hirsch E, Tabas I. 2002. Genetic alterations of IL-1 receptor antagonist in mice affect plasma cholesterol level and foam cell lesion size. Proc. Natl. Acad. Sci. USA 99:6280-85
245. Crossman DC, Morton AC, Gunn JP, Greenwood JP, Hall AS, et al. 2008. Investigation of the effect of Interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes (The MRC-ILA-HEART Study). Trials 9:8
246. Allantaz F, Chaussabel D, Stichweh D, Bennett L, Allman W, et al. 2007. Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J. Exp. Med. 204:2131-44
247. Lequerre T, Quartier P, Rosellini D, Alaoui F, De Bandt M, et al. 2008. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann. Rheum. Dis. 67:302-8
248. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, et al. 1998. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J. Clin. Invest. 102:1369-76
249. Donn R, Alourfi Z, Zeggini E, Lamb R, Jury F, et al. 2004. A functional promoter haplotype of macrophage migration inhibitory factor is linked and associated with juvenile idiopathic arthritis. Arthritis Rheum. 50:1604-10
250. Gul A. 2005. Behcet's disease as an autoinflammatory disorder. Curr. Drug Targets Inflamm. Allergy 4:81-83
251. Stojanov S, Hoffmann F, Kery A, Renner ED, Hartl D, et al. 2006. Cytokine profile in PFAPA syndrome suggests continuous inflammation and reduced anti-inflammatory response. Eur. Cytokine Netw. 17:90-97
252. Long SS. 1999. Syndrome of Periodic Fever, Aphthous stomatitis, Pharyngitis, and Adenitis (PFAPA) - What it isn't. What is it? J. Pediatr. 135:1-5